The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
23h
HealthDay on MSNDepression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in SeniorsFor older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.
GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according ...
15h
Health on MSNThyroid Cancer Is Overdiagnosed in the U.S.—Could Ozempic Be Making the Problem Worse?Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...
A live webcast will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results